Dr. Martens (LON:DOCS) Insider Buys £149.48 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 202 shares of Dr. Martens stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of GBX 74 per share, for a total transaction of £149.48.

Giles Wilson also recently made the following trade(s):

• On Wednesday, May 13th, Giles Wilson bought 233 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 64 per share, with a total value of £149.12.
• On Tuesday, April 14th, Giles Wilson purchased 232 shares of Dr. Martens stock. The stock was acquired at an average price of GBX 65 per share, with a total value of £150.80.

Dr. Martens Stock Up 0.6%

Shares of LON DOCS traded up GBX 0.40 during mid-day trading on Tuesday, reaching GBX 72.50. 377,685 shares of the company’s stock were exchanged, compared to its average volume of 8,721,683. The firm has a market capitalization of £693.89 million, a price-to-earnings ratio of 30.21, a PEG ratio of 6.40 and a beta of 0.25. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27. The business has a fifty day simple moving average of GBX 67.35 and a 200 day simple moving average of GBX 69.69. Dr. Martens plc has a twelve month low of GBX 59.15 and a twelve month high of GBX 100.87.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The business had revenue of £764.90 million during the quarter. As a group, equities analysts expect that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DOCS has been the subject of several research analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 100 price target on shares of Dr. Martens in a report on Tuesday, June 2nd. Berenberg Bank dropped their price objective on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.